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Functions of Rhomboid Family Protease RHBDL2 and
Thrombomodulin in Wound Healing
Tsung-Lin Cheng1,2, Yu-Ting Wu1, Hung-Yu Lin1, Fu-Chih Hsu2, Shi-Kai Liu1, Bi-Ing Chang2,
Wei-Sheng Chen1, Chao-Han Lai2, Guey-Yueh Shi1,2 and Hua-Lin Wu1,2
The expression of thrombomodulin (TM), a membrane glycoprotein, is upregulated in neoepidermis during
cutaneous wound healing. Rhomboid-like-2 (RHBDL2), an intramembrane serine protease, specifically cleaves
TM at the transmembrane domain and causes the release of soluble TM (sTM). However, the physiological
functions of TM and RHBDL2 in wound healing remain unclear. We demonstrated that both TM and RHBDL2 are
upregulated in HaCaT cells stimulated by scratch wounds; furthermore, increased sTM was found in culture
medium. Conversely, inhibition of RHBDL2 by 3,4-dichloroisocoumarin (DCI) or short hairpin RNA significantly
inhibited wound-induced TM ectodomain shedding and wound healing. Both conditioned media from
multiple-scratch-wounded HaCaT and recombinant sTM accelerated wound healing in HaCaT cells; such effects
were abrogated by anti-TM antibodies. The RNA released from injured cells is involved in the induction of
TM and RHBDL2. RHBDL2 and sTM were upregulated in ex vivo tissue culture of the injured skin. Furthermore,
DCI inhibited sTM production and wound healing; this was reversed by recombinant sTM in mice. Thus,
RHBDL2 and TM have important roles in wound healing via the release of sTM from keratinocytes; this may
function as an autocrine/paracrine signal promoting wound healing.
Journal of Investigative Dermatology (2011) 131, 2486–2494; doi:10.1038/jid.2011.230; published online 11 August 2011
INTRODUCTION
Thrombomodulin (TM) is a type-I transmembrane glycoprotein
that is expressed on the surfaces of endothelial cells and
epidermal keratinocytes (Esmon, 1995; Lager et al., 1995;Weiler
and Isermann, 2003). It is composed of five distinct domains: an
NH2-terminal lectin-like region (TM domain 1, TMD1), an
epidermal growth factor-like domain (TMD2) consisting of six
epidermal growth factor-like repeats, an O-glycosylation site-
rich domain (TMD3), a transmembrane domain (TMD4), and a
cytoplasmic tail (TMD5) (Figure 1a). The various biological
functions of TM domains have been demonstrated in different
physiological and pathological processes (Esmon, 1995; Healy
et al., 1995; Zhang et al., 1998; Huang et al., 2003; Shi et al.,
2005, 2008). Until now, the function of TM in epidermal
differentiation and wound healing was largely unknown,
although the expression of TM is tightly regulated during
keratinocyte differentiation (Mizutani et al., 1994; Raife et al.,
1994, 1996, 1998; Lager et al., 1995; Senet et al., 1997).
Soluble TM (sTM) in plasma and urine is found in healthy
subjects (Ishii and Majerus, 1985). It is proposed that various
proteases are responsible for the shedding and release of sTM
from the cell membrane, and that elevated plasma sTM serves
as a marker of endothelial damage (Blann and Lip, 1998). It
was recently demonstrated that TM is the specific trans-
membrane protein substrate of rhomboid-like-2 (RHBDL2), a
member of rhomboid serine protease family, in mammalian
cells (Lohi et al., 2004). Previous report indicates that the
expression of TM in keratinocytes is upregulated during
cutaneous wound healing (Peterson et al., 1999). However,
overall functions of the TM and RHBDL2 system in cutaneous
wound healing remain unknown.
As recombinant TM is a potent mitogenic factor (Shi et al.,
2005), we hypothesize that TM is cleaved by RHBDL2 at its
transmembrane domain and released from the neoepidermis
into the wound matrix. Consequently, sTM may then function
as a mitogenic factor in the healing process. To test this
hypothesis, we measured the induction of TM and RHBDL2
expression in injured keratinocytes in vitro and in the margin
of wound openings in mice. Effects of the specific knock-
down of RHBDL2 by RNA interference and an inhibitor on
wound healing were investigated. A mechanism for TM and
RHBDL2 induction in wound healing is also proposed.
RESULTS
RHBDL2 mediates the ectodomain shedding of TM from
keratinocytes
Whether the shedding of TM ectodomain occurred in the
keratinocyte remains unknown. First, we detected the TM
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domains of keratinocytes in the conditioned medium (CM).
Results showed that one major band of sTM that had a
molecular mass of B90 kDa, similar to the recombinant
ectodomain of TM (rTMD123), was detected in the CM.
The intact TM had a molecular mass 495 kDa (Figure 1d).
The molecular mass of rTMD23 was B64 kDa (Figure 1b
and c). Our result indicated that sTM might represent the
ectodomain of intact TM. The amount of the sTM found in the
CM increased in a time-dependent manner (Figure 1d).
Moreover, rhomboid serine protease inhibitor (3,4-dichlor-
oisocoumarin, DCI) inhibited the production of sTM in a
dose-dependent manner (Figure 1e). The amount of sTM
was significantly decreased by the RHBDL2 short hairpin
(sh)RNA (shRHBDL2) transfection and was increased by
RHBDL2-green fluorescent protein (GFP) overexpression
(Figure 1f). Overexpression of RHBDL2-GFP could restore
the release of sTM under conditions of DCI treatment (5 mM;
Supplementary Figure S1 online). The results imply that
RHBDL2 is involved in the shedding of TM ectodomain in
the keratinocytes.
RHBDL2 expression and sTM production are increased in the
cell culture after wounding
RHBDL2 expression and TM shedding in keratinocytes after
damage by scratch wounding have never been studied
before. The confluent HaCaT were subjected to different
numbers of scratch wounds, and samples of CM and cell
lysates were harvested 1 day after injury. Western blot
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Figure 1. Thrombomodulin (TM) is cleaved by rhomboid-like-2 (RHBDL2) to release soluble TM (sTM) from keratinocytes. (a) Illustration of the protein
domain structure of TM and recombinant TM (rTM). Arrow indicates the predicted cutting site of RHBDL2. Dotted line indicates the antibody region against
TM (D-3). Purified rTMD23 and rTMD123 were analyzed by Coomassie blue staining (b) and western blotting (c). (d) Western blot analysis of TM in HaCaT
lysates, purified rTMD123 (20 ng), and sTM in the serum-free conditioned medium (CM) collected at the indicated time points. (e) Western blotting and
quantitative representation of the sTM after treatment with 3,4-dichloroisocoumarin (DCI) for 24 hours. (f) Western blotting and quantitative representation of the
sTM from HaCaT and stable transfected cells (green fluorescent protein (GFP), RHBDL2-GFP, and shRHBDL2). *Po0.05, **Po0.01, ***Po0.001.
aa, amino acid; GST, glutathione S-transferase.
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analysis revealed a positive correlation among the number
of scratch wounds and expression of RHBDL2 and sTM
(Figure 2a). After the cells were subjected to 5 or 10 lines of
scratch wounds across the culture dish, they demonstrated an
approximately 2-fold increase in both RHBDL2 and sTM
compared with the unwounded control (Figure 2b).
The process by which scratch wounds are created in cell
cultures may lead to a significant amount of cell death, as
well as the release of cellular contents into the medium.
These contents may stimulate TM and RHBDL2 expression in
non-damaged cells. To test this hypothesis, UV-irradiated
keratinocytes (UVR cells) were used to evaluate the effects of
the substances released from dead cells. Results show that
the TM and RHBDL2 protein expression levels in normal
HaCaT were increased when stimulated by coculturing with
UVR cells. The effects of UVR cells were abolished when
pretreated with RNase but not DNase (Figure 2c and e). The
upregulation of TM and RHBDL2 by scratch wounds was also
suppressed by incubation with RNase (Figure 2d and f). The
results imply that UVR cells and scratch wounds can induce
TM and RHBDL2 expression via similar regulatory mechan-
isms; in addition, RNA release from damaged cells may have
a pivotal role in the process. However, UVR cells and scratch
wounds did not induce significant changes in the expression
of other RHBDL2 substrates, ephrin B2 and B3 (Figure 2c–f).
RHBDL2 is involved in wound-induced TM shedding from
keratinocytes
We examined whether RHBDL2 participates in the modula-
tion of TM in response to wound stimulation. The release
of sTM from keratinocytes promoted by scratch wounds
was inhibited by DCI, as shown by western blot analysis
(Figure 3a). Transient transfected RHBDL2 shRNA signifi-
cantly reduced RHBDL2 expression and sTM production
(Figure 3b). These results indicate that the inhibition of
rhomboid activity or the knockdowns of RHBDL2 can down-
regulate the release of sTM from scratch-wounded HaCaT.
The results suggest that wound-stimulated upregulation of
sTM production depends on RHBDL2 activity in the cell
culture.
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Figure 2. Injury-induced rhomboid-like-2 (RHBDL2) upregulation and
thrombomodulin (TM) ectodomain shedding in HaCaT cells were inhibited
by RNase. (a) Western blot analysis of RHBDL2 expression in cell lysates (left)
and soluble TM (sTM, right) in the conditioned medium of HaCaT after
scratch wounding. (b) Quantitative representation of the results of a. Western
blot analysis of normal HaCaT cocultured with UV-irradiated keratinocytes
(UVR cells) (c) and scratch-wounded cells (d) that were pretreated with
DNase (4Uml1) or RNase (20 mgml1). (e, f) Quantitative representation of
the results of c and d. The number of scratch wounds is five. Data are from
three independent experiments. *Po0.05, **Po0.01, ***Po0.001 versus
untreated controls. GST, glutathione S-transferase; Lys, lysate; Med, medium.
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Figure 3. Scratch-wound-induced thrombomodulin (TM) ectodomain
shedding in HaCaT cells inhibited by serine protease inhibitor
3,4-dichloroisocoumarin (DCI) and rhomboid-like-2 (RHBDL2) short
hairpin RNA (shRNA). (a) The soluble TM (sTM) in concentrated conditioned
medium and RHBDL2 in cell lysates of HaCaT cells after scratch wounding
and treatment with DCI (left panel) or transient transfection with RHBDL2
shRNA (right panel) were analyzed by western blotting. (b) Quantitative
representation of the results of a. The number of scratches is five. Data are
from three independent experiments. ***Po0.001. For all western blot
analyses, one representative experiment of three is shown. GST, glutathione
S-transferase; Lys, lysate; Med, medium.
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RHBDL2 is required for wound recovery, cell migration, and
proliferation
The stable RHBDL2-knockdown cell line was established to
evaluate the physiological effects of RHBDL2 on wound
recovery, cell migration, and proliferation. Results show that
RHBDL2 was significantly silenced in shRHBDL2-transfected
cells, and sTM becomes undetectable (Figure 4a). The rate of
wound healing was measured using a time-lapse recording
system when cells were cultured in complete medium. The
results demonstrate that the control cells transfected with GFP
were almost completely healed within 24 hours. However,
the shRHBDL2 cells were only about 50% recovered at
24 hours (Figure 4b and c). Cell migration and proliferation
are the two important factors that contribute to the rate of
wound healing. The results shown by the transwell migration
assay indicated that shRHBDL2 cells migrated slower than
HaCaT and GFP cells within 24 hours (Figure 4d). Moreover,
the cellular proliferation of shRHBDL2 cells was significantly
inhibited after 2 days of culture (Figure 4e). Thus, RHBDL2
has a significant impact on cell migration and proliferation,
and therefore is involved in the wound-healing process in
keratinocytes.
sTM and recombinant human TM domains promote epithelial
wound healing
The recombinant human TM domain (rTMD23) is a
mitogenic factor (Tohda et al., 1998; Shi et al., 2005).
The rTMD123 is also mitogenic for HaCaT (Supplementary
Figure S2 online). Therefore, RHBDL2 may promote cuta-
neous wound healing by producing sTM in situ. Serum-free
CM from the wound-stimulated HaCaT promoted the healing
of keratinocytes, and pretreatment with purified anti-TM
antibody (400 ngml1, 37 1C, 30minutes) abolished the
stimulatory effect. Moreover, the CM from shRHBDL2 cells
had no effect on wound healing. Furthermore, purified
rTMD123 (20nM) also had a similar effect as that of the CM
from wounded HaCaT (Figure 5). The results suggest that
sTM released by RHBDL2 has a significant role in wound
healing in HaCaT.
The roles of RHBDL2 and sTM in cutaneous wound healing
in vivo
To test the roles of RHBDL2 and sTM in mouse cutaneous
wound healing, we first tested how wound stimulation
regulates their expression. The results show that TM expres-
sion was elevated 1–5 days after transdermal incision surgery;
this is consistent with the results of the immunohistochemical
study (Peterson et al., 1999). RHBDL2 was also upregulated
at 3–5 days after incision (Figure 6a). Furthermore, RHBDL2
activity and TM shedding were observed in murine skin
organ cultures. Treatment with DCI reduced sTM secretion
in a dose-dependent manner, and complete inhibition was
observed at higher doses (i.e., 1mM; Figure 6b). These results
imply that RHBDL2 is involved in sTM release from injured
skin. The effects of RHBDL2 inhibitor and sTM on cutaneous
wound healing were also evaluated. Two days after incision,
DCI (1mM) or vehicle (Lipovenoes 10%) was injected
subcutaneously into the wound margin once a day for
2 days. Results indicate that the inhibitory effects of DCI on
wound healing are significantly abolished by treatment with
rTMD123 proteins (Figure 6c and d). In addition, Masson’s
trichrome and proliferating cell nuclear antigen staining
results indicated that expression of hyperproliferative epithe-
lial cells was reduced under DCI treatment, and this change
could be abolished by rTMD123 (Supplementary Figure S3
online). On the basis of these results, we propose that the
expressions of RHBDL2 and TM are upregulated, leading to
the release of sTM, which most likely has an important role in
cutaneous wound healing.
DISCUSSION
RHBDL2 has the potential to catalyze the proteolytic
cleavage of membrane-bound substrates and release soluble
protein ectodomains, including TM, ephrin B2, and B3 (Lohi
et al., 2004; Pascall and Brown, 2004). It has been shown that
TM can be efficiently and specifically cleaved by RHBDL2
(Lohi et al., 2004). As TM knockdown in mice is embryonic
lethal and no RHBDL2 knockout mice were generated,
we propose that TM shedding by RHBDL2 conceals some
unreported physiological functions. Upregulation of TM
expression was demonstrated in damaged tissues, including
the brain (Pindon et al., 2000), endothelium, and epidermis.
Until now, the mechanism of TM release and the physio-
logical function of sTM in tissue repair remained mostly
unknown. Cutaneous wounds induced prominent upregula-
tion of TM in the neoepidermis; this is an interesting model
for investigating the function of TM and RHBDL2 in tissue
damage. Results of our study provide previously unreported
evidence that the expressions of TM and RHBDL2 are
upregulated in keratinocytes after damage, both in vivo and
in vitro. The RNA released from damaged tissue may
represent one of the critical factors in the induction of TM
and RHBDL2 expression. We also demonstrated that sTM
release from culture cells or tissues is RHBDL2 dependent
and that it has a critical role in cutaneous wound healing.
These results are consistent with those of previous reports that
indicate that rTM is a mitogenic factor (Tohda et al., 1998;
Shi et al., 2005).
Seven rhomboid homologs (RHBDL1–RHBDL7) have been
identified; only RHBDL2 cleaves Drosophila Spitz (Lee et al.,
2001; Urban et al., 2001). However, little is known about the
regulatory mechanisms and physiological significance of
RHBDL2. Our results indicate that the generation of sTM
in vitro is significantly inhibited by the RHBDL2 inhibitor.
Moreover, a more specific shRHBDL2 was applied to confirm
that wound-induced sTM production is due to the catalytic
activity of RHBDL2 in keratinocytes. In addition, wounding
may evoke a large amount of necrosis or apoptosis. RNA that
released from damaged cells can induce tumor necrosis
factor-a production in keratinocytes by activation of Toll-like
receptor 3 (Kono and Rock, 2008; Lai et al., 2009). The CM of
damaged cells becomes less effective in inducing TM and
RHBDL2 after treatment with RNase. Our preliminary results
showed that pretreatment with Toll-like receptor 3 shRNA
inhibited UVR-induced upregulation of TM and RHBDL2
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(data not shown). On the basis of these results, we further
propose that the wound-induced upregulation of RHBDL2
and TM is regulated by RNA/Toll-like receptor 3 signaling
pathways.
The shRNA-induced downregulation of RHBDL2 inhibited
cell proliferation and motility, subsequently resulting in
delayed wound recovery in keratinocytes. These findings
highlight the pivotal role of RHBDL2 in regulating the growth
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and migration of epithelial cells, probably through the release
of mitogenic factors, such as sTM, or a reduction of cell–cell
adhesion as TM is also involved in cell–cell adhesion.
Soluble TM fragments are present in plasma, urine, and
synovial fluid (Jackson et al., 1994). Our study indicates that
90-kDa sTM, the same size as human rTMD123, may be
released from keratinocytes. The molecular mass of sTM is
consistent with the hypothesis that TM shedding is due to its
proteolytic cleavage by RHBDL2 at the N-terminal region
of the transmembrane domain and the fact that the entire
ectodomain of TM was identified in the culture medium
(Lohi et al., 2004).
Our results indicate that TM antibodies and DCI could
significantly retard wound healing in cultured keratinocytes
and mouse skin. These observations suggest that sTM
originates from the neoepidermis at the edge of the wound
and serves as an autocrine/paracrine growth factor that
promotes wound healing. In previous studies, various
TM-deficient mice were used to evaluate the impact of TM
during cutaneous wound healing; however, no significant
differences with respect to the rate or extent of re-epitheliali-
zation were observed (Peterson et al., 1999). In fact, these
TM-deficient, heterozygous TM-deficient (TMþ /), com-
pound heterozygous (TMpro/), and TM/ chimeric mice
were not completely null for TM. Sufficient sTM may be
released from these TM-deficient mice under conditions such
as wounding. Therefore, skin-specific TM-knockout mice or
RHBDL2-knockout mice are warranted for validating the
effects of TM or sTM in wound healing.
Wound healing is an intricate process, and many EGFR
ligands have important roles in the repair process (Schultz
et al., 1987; Greenhalgh, 1996; Steed, 1998). Interestingly,
most EGFR ligands are synthesized as membrane-anchored
forms that are subjected to proteolytic processes to generate
bioactive soluble forms (Massague and Pandiella, 1993).
The ectodomain shedding of EGFR ligands is essential
for keratinocyte migration during cutaneous wound healing
(Tokumaru et al., 2000). In this study, we demonstrated
that RHBDL2 participates in the wound repair process
by specifically releasing sTM during the early proliferative
phase. sTM may activate cell proliferation and migration
by binding to its specific receptors, which should be
identified in the future.
Inflammation is an essential protective mechanism that
occurs after injury. Toll-like receptor 3 is required for
commensal bacteria to regulate inflammation after skin injury
(Lai et al., 2009). It is interesting to note that RNA released
from the damaged tissue can stimulate upregulation of
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TM and RHBDL2, leading to the release of sTM. Recombi-
nant TMD1 can neutralize Gram-negative bacteria-induced
inflammatory responses by binding to specific Lewis Y anti-
gens (Shi et al., 2008). Therefore, upregulation of TM and
sTM may provide another mechanism for modulating
inflammatory response in wound healing.
In conclusion, our work clearly indicates that RHBDL2
expression and TM shedding have important roles in the
cutaneous wound healing process (Figure 6e). This study also
provides a foundation for exploring the potential therapeutic
effects of sTM in treating chronic wounds caused by diabetes,
chemotherapy, radiotherapy, or steroid hormones.
MATERIALS AND METHODS
Materials
The HaCaT human keratinocyte cell line was grown with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA; Huang et al., 2003). The
RHBDL2 shRNA expression vector, HuSH-29, was purchased from
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OriGene Technologies (Rockville, MD). GFP expression vector,
pEGFP-N1, was purchased from Clontech (Palo Alto, CA). Human
RHBDL2 cDNA (GeneCopoeia, Rockville, MD) was constructed into
pEGFP-N1 to generate GFP-tagged RHBDL2 expression vector,
pRHBDL2-GFP. RHBDL2 antibody was purchased from Aviva
Systems Biology (San Diego, CA). TM (D-3) antibody, b-actin
antibody, and glutathione S-transferase antibody were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The neutralizing
antibody against human TM was generated by immunizing mouse
with rTMD23 (Shi et al., 2005), and purification by protein-G column.
Expression and purification of rTMD proteins
The pCR3 vector (Invitrogen) was used for the expression and
secretion of rTMD23 and rTMD123 in the HEK293 protein expres-
sion system. DNA fragments encoding rTMD23 and rTMD123 were
obtained as described previously (Han et al., 2000). Expressed
rTMD23 or rTMD123 was applied to a nickel-chelating Sepharose
column (Amersham Phamacia Biotech, Piscataway, NJ), and rTMD-
containing fractions were eluted.
Scratch-wound stimulation
Confluent cells in six-well plate were synchronized with serum-
free DMEM for 12 hours before scratch-wound stimulation, and
then treated with different numbers of scratch wounds (0, 1, 2, 5, 10)
using a 10-ml pipette tip, and maintained under serum-free condi-
tions. After 24 hours of incubation, cell-free media were collected
and concentrated using Centricon tubes (Amicon, Beverly, MA), and
glutathione S-transferase was added (20 mg per sample) as an internal
control. The concentrated samples and cell lysates were then
subjected to western blot analysis.
UVR
Cultured human keratinocytes were irradiated by a single 30-mJ dose
of UV radiation (UV-Stratalinker 1800; Stratagene, La Jolla, CA).
After 24 hours, the UV-irradiated cells (UVR cells) were collected
and added to untreated normal keratinocytes.
Cell growth assays
HaCaT and selected stable cells were plated in six-well plates
(3 105 cells per well) with culture medium containing 10%
fetal bovine serum. To assess cell growth, the cells were
washed with phosphate-buffered saline, trypsinized, and counted
by a hemocytometer.
In vitro wound healing assay
The confluent cells in six-well plate were scratched using a 10-ml
pipette tip to generate a cell-free zone (0.6–0.8mm wide). After
extensive washing with DMEM, the cells were incubated for
24 hours at 37 1C with serum-free DMEM, indicated CM or
rTMD123. The cells were photographed using a time-lapse video
microscopy system (Olympus, Tokyo, Japan) immediately after
wounding.
Automated time-lapse video tracking
Time-lapse image acquisition was performed by serial phase-
contrast imaging every hour for 24 hours using an automated
motorized stage. A  10 objective lens was used on an inverted
Olympus IX81 microscope linked to a DP30 monochrome camera
running analySIS LS Professional software (Olympus). Cells were
only exposed to light during image acquisition. All instrumenta-
tion was enclosed in a chamber maintained at 37 1C and 5% CO2.
Stacked images were superimposed and concatenated into separated
images (.jpg file format) using Metamorph software (Universal
Imaging Corporation, Downingtown, PA). The ratio of wound
recovery was quantitatively determined with ImageJ software
(National Institutes of Health, Bethesda, MD).
shRNA-mediated RHBDL2 gene silencing
The RHBDL2 shRNA-expressing or control vector was transfected
into cells using a Lipofectamine 2000 transfection protocol (Invitro-
gen). The transfection efficiency is about 70%. Transfected cells
were then harvested for western blot analysis or for selecting stable
cell lines with puromycin 48 hours after transfection.
Western blot analysis
Total protein (30 mg) was separated using a 10% SDS-PAGE and
transferred onto a polyvinylidene difluoride membrane. The
membrane was blocked with 5% nonfat dry milk for 1 hour at room
temperature. After being probed with a primary antibody overnight
at 4 1C, the membrane was incubated with a secondary antibody
for 1 hour at room temperature. The signal was detected using
an enhanced chemiluminescence reagent (Amersham Phamacia
Biotech). The band intensity was quantitatively determined using
ImageJ software.
Transwell cell migration assay
Cell migration was analyzed using a modified Boyden chamber
assay in 24-well plates (Transwell; Costar, New York, NY). Cells
were starved by 0.1% fetal bovine serum for 18–20 hours, and placed
into the upper compartment of the chambers (1 104 cells per
chamber). Culture medium containing 10% fetal bovine serum was
added to the lower chambers. After 24 hours incubation, cells on the
upper face of the membrane were scraped off, and cells on the
lower face were fixed and stained with Liu’s solution (Handsel
Technologies, Taipei, Taiwan). The number of migrated cells on the
filters was counted in five separate fields under  100 magnification.
Assays were performed in triplicate.
Murine skin organ culture
Punch biopsies (4mm) were prepared under sterile conditions from
the back skin of adolescent C57BL/6JNarl (B6) mice (Jackson
Laboratories, Bar Harbor, ME) according to previously described
basic organ culture protocols (Li et al., 1992; Paus et al., 1994;
Spiekstra et al., 2007). The culture media were renewed two times
per week. Skin substitutes were ready for experimentation after 3
weeks of culture. After wounding and addition of DCI (0, 50, 100, or
1000mM; Sigma-Aldrich) for 48 hours, the CM was then harvested for
analysis.
In vivo cutaneous wound-healing assay
This assay was modified from Royji and Daniel (Tsuboi and Rifkin,
1990). A full-thickness 20-mm linear wound was made with a
scalpel blade on the back skin over the paravertebral area at the mid-
dorsum of each mouse. The skin surrounding the wound was treated
with injections of sterile Lipovenoes 10% (Fresenius-Kabi, Bad
Homburg, Germany) as a vehicle control, 1mM DCI, or DCI plus
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rTMD123 (125 mg kg1). This treatment was applied to the wounds
daily for 2 days at the indicated time points. The cut edge of each
wound was photographed on days 1–9 after surgery for the analysis
of wound closure by using ImageJ software. The percentage of daily
wound closure was compared with the original wound area on day 1
(Greenhalgh et al., 1990). All animal experiments were approved by
the Institutional Animal Care and Use Committee of National Cheng
Kung University, Tainan, Taiwan.
Statistical analysis
Data are expressed as mean±SEM. Statistical significance was
analyzed using one-way or two-way analysis of variance. P-values of
o0.05 were considered significant.
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